Brokerages Set Gyre Therapeutics, Inc. (NASDAQ:GYRE) Target Price at $17.00

Gyre Therapeutics, Inc. (NASDAQ:GYRE) has received an average rating of “Hold” from the five analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $17.00.

GYRE has been the topic of a number of recent analyst reports. Zacks Research upgraded shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, November 14th. Jefferies Financial Group initiated coverage on shares of Gyre Therapeutics in a research note on Friday, October 10th. They set a “buy” rating and a $16.00 price target for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Wednesday, October 8th. HC Wainwright initiated coverage on shares of Gyre Therapeutics in a research note on Tuesday, August 26th. They issued a “buy” rating and a $18.00 target price for the company. Finally, Wall Street Zen raised shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 15th.

Gyre Therapeutics Price Performance

Shares of NASDAQ:GYRE opened at $7.57 on Friday. The business’s fifty day moving average price is $7.74 and its two-hundred day moving average price is $8.06. Gyre Therapeutics has a fifty-two week low of $6.11 and a fifty-two week high of $14.42. The stock has a market capitalization of $729.24 million, a price-to-earnings ratio of 757.76 and a beta of 1.88.

Institutional Trading of Gyre Therapeutics

Large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its position in shares of Gyre Therapeutics by 18.7% during the first quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company’s stock worth $127,000 after acquiring an additional 2,596 shares in the last quarter. SBI Securities Co. Ltd. increased its holdings in Gyre Therapeutics by 87.9% during the 2nd quarter. SBI Securities Co. Ltd. now owns 232,299 shares of the company’s stock worth $1,707,000 after purchasing an additional 108,670 shares in the last quarter. Advantage Alpha Capital Partners LP increased its holdings in Gyre Therapeutics by 54.0% during the 1st quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company’s stock worth $105,000 after purchasing an additional 4,790 shares in the last quarter. American Century Companies Inc. acquired a new stake in shares of Gyre Therapeutics in the 1st quarter valued at about $184,000. Finally, Alliancebernstein L.P. raised its stake in shares of Gyre Therapeutics by 9.5% in the 3rd quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock valued at $163,000 after purchasing an additional 1,900 shares during the period. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.